FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
a study on Metastatic Castration-Resistant Prostate Cancer Prostate Cancer
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedcompletion around
- Principal Investigator
- by Jeremie Calais, MD
Description
Summary
This is an open-label, randomized, multicenter study of FPI-2265 (225Ac-PSMA-I&T). The dose optimization Phase 2 part will be investigating the safety, tolerability, and anti-tumor activity of novel dosing regimens of FPI-2265 in participants with PSMA-positive mCRPC who have been previously treated with 177Lu-PSMA-617 or another 177Lu-PSMA radioligand therapy (RLT).
Official Title
A Phase 2/3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of FPI-2265 (225Ac-PSMA-I&T) in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC), Previously Treated With 177Lu-PSMA Radioligand Therapy (RLT)
Details
The purpose of the dose optimization segment (Phase 2) is to determine the recommended FPI-2265 dose and regimen. Conclusions from Phase 2 will be based on safety, tolerability, and anti-tumor activity.
Participants with PSMA positive scans will be randomized (1:1:1) to one of three different dosing arms:
Arm 1: Will consist of nine doses of FPI-2265, administered every four weeks at 50 kBq/kg.
Arm 2: Will consist of six doses of FPI-2265, administered every six weeks at 75 kBq/kg.
Arm 3: Will consist of four doses of FPI-2265, administered every eight weeks at 100 kBq/kg.
Participants will be monitored and assessed for efficacy response, disease progression and adverse events.
Keywords
Metastatic Castration-resistant Prostate Cancer, mCRPC, 225Ac-PSMA-I&T, Radioligand therapy, Prostatic Neoplasms, FPI-2265, FPI-2265 50 kBq/kg, FPI-2265 75 kBq/kg, FPI-2265 100 kBq/kg
Eligibility
You can join if…
Open to males ages 18 years and up
- Ability to understand and sign an approved informed consent form (ICF) and comply with all protocol requirements.
- Phase 2: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1
- Diagnosis of adenocarcinoma of prostate proven by histopathology.
- Must have had prior orchiectomy and/or ongoing androgen-deprivation therapy and a castrate level of serum/plasma testosterone
- Progressive mCRPC.
- Must have been previously treated with lutetium-PSMA therapy (lutetium-177 vipivotide tetraxetan or other lutetium-177-PSMA RLT). Treatment must have been completed >6 weeks prior to the first dose of study drug.
- Participants with known BRCA mutations should have received FDA-approved therapies such as PARP inhibitors, per Investigator discretion.
- Positive PSMA PET/CT scan
- Adequate organ function
- For participants who have partners of childbearing potential: Partner and/or participant must not be planning to conceive and must use a method of birth control with adequate barrier protection deemed acceptable by the Principal Investigator during the study treatment and for six months after last study drug administration.
You CAN'T join if...
- Participants who received more than two prior lines of cytotoxic chemotherapy for CRPC.
- Phase 2: participants who progress within two cycles of prior treatment with 177Lu-PSMA therapy
- All prior treatment-related adverse events must have resolved to Grade ≤1 (CTCAE v5.0). Alopecia and stable persistent Grade 2 peripheral neuropathy may be allowed at the discretion of the Investigator.
- Participants with known, unresolved, urinary tract obstruction are excluded.
- Administration of any systemic cytotoxic or investigational therapy ≤30 days of the first dose of study treatment or five half-lives, whichever is shorter. Completion of large-field external beam radiotherapy ≤four weeks of the first dose of study treatment.
- Participants with a history of central nervous system (CNS) metastases are excluded except those who have received therapy
- Participants with any liver metastases will be excluded from the Phase 2 segment of the study.
- Participants with skeletal metastases presented as a superscan on a ⁹⁹ᵐTc bone scan.
- Previous or concurrent cancer that is distinct from the cancer under investigation in primary site or histology, except treated cutaneous basal cell carcinoma or squamous cell carcinoma and superficial bladder tumors. Any cancer curatively treated >two years prior to the first dose of treatment is permitted.
- Concurrent serious (as determined by the investigator) medical conditions
- Major surgery ≤30 days prior to the first dose of study treatment.
Locations
- University of California Los Angeles
accepting new patients
Los Angeles California 90095 United States - VA Greater Los Angeles Healthcare System
accepting new patients
Los Angeles California 90073 United States - City of Hope Comprehensive Cancer Center
accepting new patients
Duarte California 91010 United States
Lead Scientist at UCLA
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Fusion Pharmaceuticals Inc.
- Links
- Sign up for this study
- ID
- NCT06402331
- Phase
- Phase 2/3 research study
- Study Type
- Interventional
- Participants
- Expecting 60 study participants
- Last Updated
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Submitting your contact information does not obligate you to participate in research.
Thank you!
The study team should get back to you in a few business days.